Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 10 of these applications claim priority to application PCT/US2016/052352, filed Sep 16, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,867,888 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence UsedRemaining | ModernaTX, Inc. | In force | High confidence | ||
| US 9,868,691 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 9,868,692 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 9,868,693 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 10,266,485 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 10,392,341 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 10,442,756 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 12,151,995 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 12,404,232 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 11,220,476 | Compounds and Compositions for Intracellular Delivery of Therapeutic Agents In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| 1 more record in this group · Pro | ||||||
10 of 11 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 11.
10 of these are in force and held by ModernaTX, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.